source
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion, expanding siRNA portfolioMerck KGaA, the German science and technology conglomerate, announced an agreement to purchase UK‑based Silence Therapeutics. The deal is valued at about $1.3 billion and gives Merck access to Sil…
- Merck KGaA to acquire Silence Therapeutics for $1.1 billion, gaining Phase 3 PV siRNA assetMerck KGaA announced it will buy Silence Therapeutics for about $1.1 billion, giving the German group a foothold in hematology. Silence, a UK-based RNA specialist, develops short interfering RNA m…